ABSTRACT BACKGROUND Risk stratification in asymptomatic patients remains by far the most important yet unresolved clinical
B rugada syndrome (BrS) is characterized by
ST-segment elevation in the right precordial leads and an increased risk of ventricular fibrillation (VF) and sudden cardiac death (SCD) (1, 2) . The real incidence of SCD in these patients is uncertain, and controversy exists with regard to risk stratification in asymptomatic subjects (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Certain electrocardiographic (ECG) markers of ventricular depolarization and repolarization have been reported to identify high-risk patients with BrS The so-called third vector, which is directed upward and somewhat to the right and backward, generates the S-wave in lead I (22) . This vector is determined by electrical activation of the basal region of both ventricles and by depolarization of the RVOT. A prominent S-wave in lead I is typically present in cases of congenital heart disease, valvular heart disease, and cor pulmonale that cause right ventricular (RV) enlargement and fibrosis (22) . Thus, we hypothesized that a deep and/ or large S-wave in lead I in BrS would reveal a conduction delay over the RVOT and could be used to identify high-risk patients.
The purposes of this study, conducted in a large population of patients with BrS, were to verify the usefulness of the previously proposed ECG markers of SCD and to analyze the potential role of the S-wave in lead I as a new prognostic ECG parameter to predict VF/SCD during follow-up.
METHODS STUDY POPULATION.
Of a study population of 655 subjects affected by BrS, we analyzed data from 347 consecutive patients (78.4% male; mean age 45 AE 13.1 years) with spontaneous type 1 BrS ECG phenotype (coved ST-segment elevation >2 mm in at least 1 right precordial lead). These subjects were prospectively enrolled in 4 Italian tertiary cardiology centers since 1999 (Policlinic Casilino, Rome; Città della Salute e della Scienza Hospital, Torino; Policlinic Sandro Pertini, Rome; Cardiology Clinic, Ospedali Riuniti Umberto I-Lancisi-Salesi, Ancona).
The study was approved by the local Institutional Review Boards of each participating institution, and each subject gave consent to participate in the study.
After enrollment, all subjects were prospectively followed with periodic cardiological visits including a resting 12-lead ECG study, performed at least every year or in case of symptoms. We did not include patients with BsS who had a history of VF or aborted SCD at presentation in this study. The family medical history was obtained at the first clinical visit and was considered positive if at least 1 first-degree family member had died suddenly with a type 1 Brugada ECG pattern or before the age of 45 years in the absence of known heart disease. All patients underwent transthoracic echocardiography and Holter ECG monitoring. Genetic testing and cardiac magnetic resonance were carried out at the discretion of the physicians, in line with each center's clinical practice.
ELECTROCARDIOGRAPHIC ANALYSIS. ECG studies were recorded at a paper speed of 25 mm/s and at a standard gain of 1 mV/cm. Two independent cardiologists (C.L. and M.A.) examined and interpreted all ECG tracings by using a magnifying glass, and discrepancies were resolved by consensus. The ECG tracing recorded at the patient's inclusion in the study was used for the analysis, and these tracings were analyzed with no patients receiving antiarrhythmic drugs.
The heart rate and QRS axis were manually calculated. The QRS interval duration and the PR, JT, and QT intervals were measured in the II and V 6 leads with calipers by physicians who were blinded to historical data. A PR interval >200 ms and a QRS interval duration >120 ms were considered abnormal (23) . 
Calò et al. Table 2) .
ELECTROCARDIOGRAPHIC FINDINGS. Interobserver variability for ECG parameters indicated good agreement. Online Table 1 shows the interobserver variability for each ECG parameter in detail.
ECG findings of the study population are presented in Table 3 . The mean amplitude of the R-wave in lead V 1 and the S-wave in lead V 6 did not significantly differ among patients who developed VF/SCD or syncope and those who remained asymptomatic during follow-up ( Table 3 ). The prevalence of V 1 R >0.15 mV, V 6 S >0.15 mV, and V 6 S/R >0.2 mV was similar in the 3 groups ( Table 3 ). The mean amplitude and duration of the S waves in lead II and III were similar among patients in the different groups (Table 3) . Table 4) .
Patients with a significant S-wave in lead I were relatively younger and more likely to develop VF/SCD during follow-up. ECG parameters did not differ between groups, apart from a longer QRS interval duration in leads V 2 and II and a higher incidence of complete RBBB and first atrioventricular block in patients with a significant S-wave in lead I. Table 2 . Figure 5 shows 2. In the multivariate regression analysis, the duration of the S-wave in lead I $40 ms (hazard ratio:
39.1) and AF (hazard ratio: 3.7) were independent predictors of VF/SCD during follow-up.
3. Electroanatomic mapping in 12 patients showed that the endocardial activation time was Abbreviations as in Tables 1 to 3 . Second, over the years, several prognostic parameters (including markers of conduction delay) have been proposed in BrS. However, none proved useful in larger studies. Such could also be the case for the Swave in lead I. Therefore, an independent confirmation cohort is necessary to confirm the value of the current study. Notably, because the cutpoints of the S-wave in lead I were identified and evaluated on the same dataset, they will require validation in a separate sample of healthy subjects.
Third, a potential limitation is that the ECG analysis could be influenced by the orientation of the RVOT because it could change the terminal vector of the QRS interval, particularly in some patients with significant deviation.
Another limitation is that our centers are institutions that treat cardiac arrhythmias. Therefore, with BrS. However, the prognostic value of a significant S wave in lead I should be confirmed by larger studies and by an independent confirmation cohort of healthy subjects.
